ArticleOne health outlook2026
Beyond counting the numbers - focused outbreaks response strategies are needed to control the mpox outbreak in Africa.
Article in One health outlook, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite ongoing prevention and control efforts, the mpox outbreak in Africa has persisted. Between 1 January 2024 and 7 December 2025, a total of 60,997 confirmed cases and 244 deaths have been reported across 34 African countries. Notably, 70% of these cases (n = 43,052) occurred in the 2025, indicating a marked escalation in outbreak intensity. The epicentre of transmission has shifted from Central Africa, where clade I (a and b) of the mpox virus predominates to West Africa, where clade II (a and b) is now more prevalent highlighting a widening and more diffuse spread of the outbreak. In this article, we examine the key drivers sustaining transmission using a narrative synthesis approach and propose practical, evidence-based recommendations to halt further spread. MAIN TEXT: While several structural and systemic factors are responsible for the persistent transmission of mpox, we argue that the immediate challenge lies in the suboptimal strategic implementation of existing outbreak response interventions. Our analysis identifies seven key drivers of the ongoing spread namely inadequate surveillance and laboratory investigation strategies, weak data management systems and underreporting and insufficient follow-up of contacts. Other drivers are the widespread use of home-based care for confirmed cases, often in settings with poor infection prevention and control, limited community engagement, participation and ownership of outbreak response efforts and poorly targeted vaccination interventions, largely due to weak or incomplete data and the chronic conflicts in some of the affected countries. To address these issues, we recommend a shift toward more evidence-informed and context-specific implementation of traditional prevention and control measures. Specifically, we call for alignment of surveillance strategies with local mpox epidemiology and transmission dynamics, strengthening laboratory capacity, including genomic sequencing and revision of case definitions based on current clinical and epidemiological data. Additionally, we recommend enhancement of outbreak data management systems with digital and innovative technologies, adoption of evidence-based and context-specific risk communication and community engagement and case management models and deployment of data-driven vaccination strategies.
conclusionConsidering the foregoing, there is an urgent need to rethink and refocus current mpox outbreak response strategies in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.